| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8275698 | Journal of the Neurological Sciences | 2015 | 9 Pages |
Abstract
Although CSF Aβ40 does not appear to have an additional value in the distinction between FTLD and AD, it increases the discrimination between subjects with dementia from controls. A CSF-AD biomarker profile can be seen in patients with a clinical phenotype of FTLD, reinforcing the need for autopsy confirmation.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Ageing
Authors
Inês Baldeiras, Isabel Santana, Maria João Leitão, Maria Helena Ribeiro, Rui Pascoal, Diana Duro, Raquel Lemos, Beatriz Santiago, Maria Rosário Almeida, Catarina Resende Oliveira,